T1	CHEM 16 26	Tadalafilo
#1	AnnotatorNotes T1	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T2	CHEM 30 41	Sildenafilo
#2	AnnotatorNotes T2	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T3	DISO 69 87	disfunción eréctil
#3	AnnotatorNotes T3	C0242350; Erectile dysfunction; Disease or Syndrome
T4	PROC 118 153	estudio multicéntrico internacional
T5	CHEM 206 217	sildenafilo
#4	AnnotatorNotes T5	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T6	CHEM 222 232	tadalafilo
#5	AnnotatorNotes T6	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T7	PROC 498 526	distribuyeron aleatoriamente
#6	AnnotatorNotes T7	C0034656; Randomization; Research Activity
T8	DISO 318 336	disfunción eréctil
#7	AnnotatorNotes T8	C0242350; Erectile dysfunction; Disease or Syndrome
T9	PROC 406 465	estudio multicéntrico, de 2 periodos, cruzado y doble-ciego
#8	AnnotatorNotes T9	C1096776; Multicenter Study; Research Activity + C0150097; Cross-Over Studies; Research Activity + C0013072; Double-Blind Method; Research Activity
T10	CHEM 540 551	sildenafilo
#9	AnnotatorNotes T10	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T11	CHEM 562 572	tadalafilo
#10	AnnotatorNotes T11	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T12	PROC 737 749	tratamientos
#11	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	DISO 1637 1639	DE
#12	AnnotatorNotes T13	C0242350; Erectile dysfunction; Disease or Syndrome
T14	PROC 926 937	tratamiento
#13	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 972 1003	instrucciones de administración
T16	CHEM 1007 1018	sildenafilo
#14	AnnotatorNotes T16	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T17	CHEM 1041 1051	tadalafilo
#15	AnnotatorNotes T17	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T18	PROC 1143 1154	tratamiento
#16	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 1179 1190	sildenafilo
#17	AnnotatorNotes T19	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T20	CHEM 1311 1319	fármacos
#18	AnnotatorNotes T20	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T21	PROC 1336 1349	instrucciones
#19	AnnotatorNotes T21	C0220931; Training; Educational Activity
T22	DISO 1402 1428	enfermedades concomitantes
#20	AnnotatorNotes T22	C0243087; concomitant disease; Pathologic Function
T23	CHEM 1445 1456	sildenafilo
#21	AnnotatorNotes T23	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T24	CHEM 1541 1551	tadalafilo
#22	AnnotatorNotes T24	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T25	CHEM 1599 1610	sildenafilo
#23	AnnotatorNotes T25	C0529793; sildenafil; Organic Chemical · Pharmacologic Substance
T26	PROC 1617 1628	tratamiento
#24	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	PROC 244 275	instrucciones de administración
T28	PROC 652 671	régimen alternativo
T29	PROC 848 879	instrucciones de administración
T30	CHEM 942 952	tadalafilo
#25	AnnotatorNotes T30	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T31	CHEM 1159 1169	tadalafilo
#26	AnnotatorNotes T31	C1176316; tadalafil; Organic Chemical · Pharmacologic Substance
T32	PROC 1270 1301	instrucciones de administración
T33	PROC 1558 1589	instrucciones de administración
T34	DISO 338 340	DE
#27	AnnotatorNotes T34	C0242350; Erectile dysfunction; Disease or Syndrome
T35	LIVB 45 54	pacientes
#28	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 283 303	cohorte de pacientes
#29	AnnotatorNotes T36	C0599755; Cohort; Population Group + C0030705; Patients; Patient or Disabled Group
T38	LIVB 366 375	pacientes
#31	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	LIVB 475 484	pacientes
#32	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Dose 553 558	50 mg
T41	Dose 574 579	20 mg
T42	Duration 599 609	12 semanas
T43	Duration 678 688	12 semanas
T44	LIVB 884 893	pacientes
#33	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	Dose 953 958	20 mg
T46	LIVB 1080 1089	pacientes
#34	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T48	LIVB 1519 1528	pacientes
#35	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
A1	Status T23 History_of
R1	Experiences Arg1:T35 Arg2:T1	
R2	Experiences Arg1:T35 Arg2:T2	
R3	Experiences Arg1:T35 Arg2:T3	
R4	Experiences Arg1:T36 Arg2:T8	
R5	Experiences Arg1:T36 Arg2:T34	
R6	Experiences Arg1:T36 Arg2:T6	
R7	Experiences Arg1:T36 Arg2:T5	
R8	Before Arg1:T7 Arg2:T10	
R9	Experiences Arg1:T38 Arg2:T11	
R10	Experiences Arg1:T38 Arg2:T10	
R11	Has_Dose_or_Strength Arg1:T11 Arg2:T41	
R12	Has_Dose_or_Strength Arg1:T10 Arg2:T40	
R13	Experiences Arg1:T39 Arg2:T10	
R14	Experiences Arg1:T39 Arg2:T11	
R15	Has_Duration_or_Interval Arg1:T11 Arg2:T42	
R16	Has_Duration_or_Interval Arg1:T10 Arg2:T42	
T37	CONC 581 590	a demanda
#30	AnnotatorNotes T37	C0679686; treatment on demand; Intellectual Product
R18	Before Arg1:T10 Arg2:T28	
R17	Before Arg1:T11 Arg2:T28	
R19	Has_Duration_or_Interval Arg1:T28 Arg2:T43	
R20	Used_for Arg1:T11 Arg2:T12	
R21	Used_for Arg1:T10 Arg2:T12	
R22	Experiences Arg1:T44 Arg2:T14	
R23	Used_for Arg1:T30 Arg2:T14	
R24	Has_Dose_or_Strength Arg1:T30 Arg2:T45	
R25	Used_for Arg1:T16 Arg2:T15	
R26	Used_for Arg1:T17 Arg2:T15	
R27	Used_for Arg1:T6 Arg2:T27	
R28	Used_for Arg1:T5 Arg2:T27	
R29	Used_for Arg1:T16 Arg2:T29	
R30	Used_for Arg1:T17 Arg2:T29	
R31	Used_for Arg1:T31 Arg2:T18	
R32	Used_for Arg1:T19 Arg2:T18	
R33	Experiences Arg1:T46 Arg2:T18	
R34	Used_for Arg1:T20 Arg2:T32	
R35	Used_for Arg1:T20 Arg2:T21	
T47	Neg_cue 1380 1382	no
T49	CONC 1383 1388	varió
A2	Assertion T49 Negated
#36	AnnotatorNotes T49	C1705241; Delta (difference); Quantitative Concept
R36	Negation Arg1:T47 Arg2:T49	
R37	Experiences Arg1:T48 Arg2:T24	
R38	Experiences Arg1:T48 Arg2:T25	
R39	Used_for Arg1:T25 Arg2:T26	
R40	Used_for Arg1:T24 Arg2:T26	
R41	Experiences Arg1:T48 Arg2:T13	
R42	Used_for Arg1:T25 Arg2:T33	
R43	Used_for Arg1:T24 Arg2:T33	
R44	Before Arg1:T7 Arg2:T11	
R45	Used_for Arg1:T10 Arg2:T28	
R46	Used_for Arg1:T11 Arg2:T28	
T50	Observation 1094 1116	finalizaron el estudio
#37	AnnotatorNotes T50	C2732579; Completion of clinical trial; Finding
A3	Experiencer T35 Patient
A4	Experiencer T36 Patient
A5	Experiencer T38 Patient
A6	Experiencer T39 Patient
A7	Experiencer T44 Patient
A8	Experiencer T46 Patient
A9	Experiencer T48 Patient
